Talha Badar, Hematologist-Oncologist at Mayo Clinic, shared on X:
“ASH 2026 Weekend Review: TP53-Mutated Myeloid Neoplasms
Lots to unpack across biology, prognosis, transplant and emerging therapeutic vulnerabilities. 15 abstracts that caught my attention:
- O-glycosylated CD43: Identifies O-glycosylated CD43 as a potential immune-evasion pathway & therapeutic target in TP53-mut AML.
- Allo-HCT in TP53-mut AML :Among pts achieving MLFS, HCT improved OS (17.7 vs 10 mo) & RFS (19.2 vs 9.2 mo), with benefit in single- & double-hit disease.
- Hyperinflammation in TP53-mut AML ~10% developed an acute hyperinflammatory syndrome, often early with HMA/VEN, characterized by ↑TNF-α/sIL-2Rα but absent IFN-γ.
- ATR inhibition + decitabine Phase I study testing ATRN-119 + decitabine, exploiting potential ATR dependency from replication stress in TP53-mut AML/HR-MDS.
- PPM1D TP53: Our multicenter study shows PPM1D-mut myeloid neoplasms are clinically/genomically distinct from TP53-mut disease despite convergence on DNA-damage response.
- Chromosome 17 matters: Chromosome 17 abnormalities & allo-HCT emerge as independent survival predictors in TP53-mut myeloid neoplasms.
- Occult multi-hit TP53 : TP53-region LOH testing reclassified 32% of presumed single-hit pts as multi-hit, with outcomes resembling conventional multi-hit disease.
- TP53 + germline DDX41: Somatic TP53 mutations attenuate the otherwise favorable prognosis of germline DDX41-mut myeloid neoplasms.
- TP53 clones after HCT: Our study tracks post-HCT relapse of monoallelic vs multi-hit TP53 disease, highlighting differences in clonal evolution after transplant.
- Simplifying TP53 complexity: In >3,000 pts, multi-hit status was generally a practical proxy for biallelic TP53 inactivation, but CN-LOH deserves specific assessment.
- Does TP53 function matter GOF, DN & LOF mutations had similar outcomes. Allelic state mattered more: biallelic disease mOS 8.3 vs 16.7 mo.
- Not all TP53-mut disease is the same: Our 700-pt COMMAND consortium study identified ~10% with targetable co-mutations & better OS (14.4 vs 6.1 mo). With HMA/VEN: CRc 84.6% vs 53.4%; OS 17.4 vs 5.7 mo. A potentially VEN-sensitive TP53 subset.
- Multi-hit TP53 across MDS to AML. Its adverse prognostic effect attenuates with increasing blast burden but persists in AML, suggesting allelic state & disease phenotype interact
- Post-HCT IFN-α maintenanc. Prospective phase II study evaluating IFN-α maintenance after allo-HCT for TP53-mut AML/MDS, targeting the major challenge of post-HCT relapse.
- Harmonizing TP53 classification. Our international collaboration addresses differences in TP53 classification & prognostication, critical for practice, trials & comparing outcomes.
Take-home: TP53 disease is not one entity. Allelic state, LOH, cytogenetics & co-mutations matter, while HCT and emerging molecularly informed strategies continue to evolve.”
Read more articles about Leukemia on OncoDaily.